Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Basal Cell Carcinoma Carcinoma Carcinoma, Basal Cell Disease Attributes Facies Neoplasms Neoplasms by Histologic Type Neoplasms, Basal Cell Neoplasms, Glandular and Epithelial Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Texas Health Science Center of Houston Dermatology Clinic

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Nodular or superficial basal cell carcinoma on the skin excluding scalp or face

Exclusion criteria

Pregnancy

Treatment and study plan

Imiquimod and Interferon alpha

Biological

Imiquimod first two weeks and last two weeks. Interferon middle five weeks.

Primary outcomes

resolution of basal cell carcinoma

Time frame: 2 years

Secondary outcomes

resolution of basal cell carcinoma at a lower cost and less inflammation.

Time frame: 2 years

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Registry information

Official study title

Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp

Important dates

Study start: 2007
Primary completion: 2011
Study completion: 2011
First posted: Dec 27, 2007
Registry last updated: Jan 25, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed